US20210113482A1 - Poly (Alkyl Cyanoacrylate) Nanoparticles for Use in Treatment of Cancer - Google Patents

Poly (Alkyl Cyanoacrylate) Nanoparticles for Use in Treatment of Cancer Download PDF

Info

Publication number
US20210113482A1
US20210113482A1 US17/041,094 US201917041094A US2021113482A1 US 20210113482 A1 US20210113482 A1 US 20210113482A1 US 201917041094 A US201917041094 A US 201917041094A US 2021113482 A1 US2021113482 A1 US 2021113482A1
Authority
US
United States
Prior art keywords
cbz
nps
pebca
drug delivery
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/041,094
Other languages
English (en)
Inventor
Yrr Mørch
Ruth Schmid
Einar Sulheim
Per Stenstad
Heidi Johnsen
Kirsten Sandvig
Gunhild Maelandsmo
Tore Skotland
Kjersti Flatmark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oslo Universitetssykehus hf
Sintef Tto AS
Original Assignee
Oslo Universitetssykehus hf
Sintef Tto AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo Universitetssykehus hf, Sintef Tto AS filed Critical Oslo Universitetssykehus hf
Assigned to SINTEF TTO AS, OSLO UNIVERSITETSSYKEHUS HF reassignment SINTEF TTO AS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FLATMARK, KJERSTI, JOHNSEN, HEIDI, MAELANDSMO, GUNHILD, MORCH, YRR, SANDVIG, KIRS, SCHMID, RUTH, SKOTLAND, Tore, STENSTAD, PER, SULHEIM, Einar
Publication of US20210113482A1 publication Critical patent/US20210113482A1/en
Assigned to OSLO UNIVERSITETSSYKEHUS HF, SINTEF TTO AS reassignment OSLO UNIVERSITETSSYKEHUS HF CORRECTIVE ASSIGNMENT TO CORRECT THE 6TH INVENTOR'S NAME PREVIOUSLY RECORDED AT REEL: 055144 FRAME: 0352. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Assignors: FLATMARK, KJERSTI, JOHNSEN, HEIDI, MAELANDSMO, GUNHILD, MØRCH, Yrr, SANDVIG, KIRSTEN, SCHMID, RUTH, SKOTLAND, Tore, STENSTAD, PER, SULHEIM, Einar
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the invention is related to the field nanoparticles and medical use.
  • it relates to an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer.
  • nanotechnology offers many exciting possibilities with potential in a number of medicinal applications envisaged.
  • nanomedicine is expected to lead to big improvements in the treatment of complex diseases.
  • Two areas in which the use of nanoparticles has begun to demonstrate particular value are drug delivery and molecular imaging.
  • PACA Poly(alkyl cyanoacrylate)
  • WO2014191502 A1 discloses a one-step polymerization process for preparing stealth NPs of PACA homopolymer or copolymer comprising anionic polymerization of an oil-in-water miniemulsion.
  • a miniemulsion in combination with a particular class of polyalkylene glycol derivatives, it is possible to covalently attach targeting moieties to polyalkylene glycols, thereby enabling the simultaneous introduction of a targeting group and formation of a stealth corona.
  • the miniemulsion may contain active agents, and a list of therapeutic agents are disclosed. However, none of the examples include encapsulation of any of these agents, and neither in vitro nor in vivo data are disclosed.
  • NP encapsulated drug delivery may demonstrate reduced toxicity.
  • EPR enhanced permeability and retention
  • NPMBs polymeric nanoparticles
  • CBZ cabazitaxel
  • Breast cancer is the most common non-cutaneous malignancy in women and second only to lung carcinoma in cancer mortality. There are several types of breast cancer, and in the last decade it has been possible to preform molecular classification of breast cancer based on gene expression profiles. Analyses of human breast tumors have revealed remarkably robust molecular subtypes with distinctive gene signatures and clinical outcome (Toft and Cryns, Mol Endocrinol. 2011 February; 25(2): 199-211.). Basal-like breast cancer (BLBC) is a particularly aggressive molecular subtype defined by a robust cluster of genes expressed by epithelial cells in the basal or outer layer of the adult mammary gland. BLBC is a major clinical challenge because these tumors are prevalent in young women, often relapsing rapidly.
  • BLBC basal-like breast cancer
  • basal-like tumors lack expression of steroid hormone receptors (estrogen receptor and progesterone receptor) and human epidermal growth factor receptor 2, limiting targeted therapeutic options for these predominantly triple-negative breast cancers.
  • steroid hormone receptors estrogen receptor and progesterone receptor
  • human epidermal growth factor receptor 2 limiting targeted therapeutic options for these predominantly triple-negative breast cancers.
  • no targeted therapies are available, and the patients would therefore benefit from improved chemotherapy regimens.
  • prostate cancer The male counterpart to breast cancer is prostate cancer. It is the most common cancer among men, and develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other area of the body, particularly the bones and lymph nodes. Prostate cancer can often be treated successfully if found in the early stages.
  • Taxanes are important chemotherapeutic agents with proven efficacy in human cancers. Taxanes include paclitaxel, docetaxel, cabazitaxel and their pharmaceutically acceptable salts. Paclitaxel was originally derived from the Pacific yew tree. Docetaxel is a semi-synthetic analogue of paclitaxel. CBZ, which has been characterized by Vrignaud et al (2013), is a relatively novel semi-synthetic taxane derivative. CBZ has a potent cytostatic effect by microtubule stabilization but its use has been limited due to its toxicity. CBZ has been included in several clinical trials investigating efficacy against several types of cancer. It has been approved by the US Food and Drug Administration (FDA) for treatment of refractory prostate cancer as a second line drug after docetaxel chemotherapy. Taxanes present difficulties in formulation as medicines because they are poorly soluble in water.
  • FDA US Food and Drug Administration
  • the new drug delivery system is capable of delivering hydrophobic and/or poorly soluble therapeutic agents.
  • the drug delivery system is suitable for treatment of tumors where no targeted therapies are available.
  • a drug delivery system comprising PEGylated poly (alkyl cyanoacrylate) (PACA) nanoparticles (NPs) loaded with cabazitaxel (CBZ), or a pharmaceutically acceptable salt thereof, for use in treatment of cancer, provided that the drug delivery system does not comprise NP-stabilized microbubbles (MBs).
  • PEGylated poly (alkyl cyanoacrylate) (PACA) nanoparticles (NPs) loaded with cabazitaxel (CBZ), or a pharmaceutically acceptable salt thereof for use in treatment of cancer, provided that the drug delivery system does not comprise NP-stabilized microbubbles (MBs).
  • the drug delivery system does not comprise NPs that stabilize the MBs or NPs that are used to stabilize gas-filled MBs. In another embodiment, the drug delivery system does not comprise NPs that are associated with the MBs. In yet another embodiment, the drug delivery system does not comprise gas-filled MBs. In a further embodiment, the drug delivery system does not comprise MBs.
  • the PACA NPs are produced according to a miniemulsion anionic polymerization process.
  • the NPs are further surface modified by a targeting moiety.
  • the PACA NP is below 800 nm, such as in a range selected from 1-800 nm or 10-500 nm or 70-150 nm.
  • the CBZ comprises 1-90 wt % of the NP, preferentially 5-50 wt % of the NP, more preferentially 5-20 wt % or most preferentially 5-15 wt % of the NP.
  • CBZ comprises from 6-13 wt % of the NP, more particularly about 6, 7, 8, 9, 10, 11, 12 or 13 wt % of the NP.
  • the drug delivery system is administered parenterally and may further comprising pharmaceutically acceptable excipients.
  • the cancer is a tumor in a vascular phase.
  • the tumor belongs to a type of cancer selected from the group consisting of prostate cancer, breast cancer, glioma, lung cancer, adrenocortical carcinoma, testicular cancer, urothelium transitional cell carcinoma and ovarian cancer.
  • the drug delivery system is for use in prophylactic treatment of cancer to prevent metastasis through the lymph node.
  • the drug delivery system is for use as an immune modulator and/or as a vehicle to enhance the therapeutic effect of encapsulated drugs.
  • a method for treating cancer comprising administering a drug delivery system according to the first aspect to a patient in need thereof.
  • composition or solution comprising the drug delivery system according to the first aspect of the invention.
  • the composition or solution may be a pharmaceutical formulation comprising pharmaceutically acceptable excipients and diluents.
  • FIG. 1 Size distribution of the batches used in the MAS98.12 efficacy study.
  • the size distributions for PEBCA-CBZ (the batch with size z-average of 215 nm in Table 1) is shown in dark blue and for PEBCA (without drug; the batch with z-average of 156 nm in Table 1) is shown in light blue.
  • the size distribution of non-encapsulated CBZ, solubilized in a polysorbate 80 solution, is shown in red. Intensity (%) on the y-axis means percent intensity of total scattering.
  • FIG. 2 Treatment efficacy and toxicity studied in mice bearing MAS98.12 patient derived xenograft (PDX) breast tumor models.
  • PEBCA-CBZ and CBZ were injected 2 ⁇ 15 mg CBZ/kg body weight at day 33 and 36, indicated by the red arrows.
  • FIG. 3 Biodistribution of PEBCA particles containing the fluorescent dye NR668 measured in MAS98.12 tumor-bearing mice.
  • Whole body images were obtained with IVIS 1, 4, 24 and 96 h after intravenous administration of the NPs; color scale on the right indicates radian efficiency ⁇ 10 9 (A).
  • Ex vivo fluorescence images of isolated organs were obtained 24 h after injection (B). Quantification of fluorescence intensity as relative radiant efficiency per region of interest pixel data of tissues collected 24 h after injection (C). Mean values obtained for 2 animals; error bars show estimated SD values.
  • PEBCA-CBZ PEBCA containing CBZ and NR668; PEBCA: PEBCA containing NR668, but not CBZ.
  • LNs lymph nodes.
  • FIG. 5 Macrophage infiltration in treated MAS98.12 tumors.
  • the macrophage infiltration was measured in the MAS98.12 tumors 96 h after injection of saline (control), PEBCA NPs (without drug), non-encapsulated CBZ, and PEBCA-CBZ.
  • A) The total population of infiltrated macrophages was quantified using an antibody to CD68.
  • B) The population of anti-tumorigenic (pro-inflammatory) macrophages was quantified using an antibody to iNOS.
  • C The population of pro-tumorigenic (anti-inflammatory) macrophages was quantified with an antibody to CD206.
  • FIG. 6 Treatment efficacy in the MAS98.12 PDX model.
  • Each bar represents the mean area under the curve (AUC) of individual MAS98.12 tumors shown in FIG. 2 .
  • FIG. 7 Treatment efficacy in mice bearing MDA-MB-231 tumors. Tumor growth inhibition was measured following two injections of PEBCA-CBZ, non-encapsulated CBZ, PEBCA NPs without drug and saline. The red arrows indicate days for injections. PEBCA-CBZ and CBZ were injected at 2 ⁇ 15 mg CBZ/kg; PEBCA particles not containing drug were injected 2 ⁇ 175 mg (similar to the amount of NPs in the PEBCA-CBZ group); 2 ⁇ 0.1 ml per 10 g body weight of saline were injected as a control.
  • FIG. 8 Ex vivo fluorescence images of isolated organs obtained after injection of PEBCA particles containing NR668. Images are shown for organs taken 1 h, 4 h and 96 h after injection of the particles (images taken 24 h after injection are shown in FIG. 3 ). LNs: lymph nodes.
  • FIG. 9 Immunohistochemical staining of macrophage infiltration in treated MAS98.12 tumors.
  • the macrophage infiltration was measured in the tumors 96 h after injection of saline (control), PEBCA NPs (without drug), non-encapsulated CBZ, and PEBCA-CBZ (left to right columns).
  • FIG. 10 In vitro toxicity measured as cell viability and cell proliferation in three breast cancer cell lines.
  • PEBCA-CBZ with 100 nM CBZ contains 4.5 ⁇ g/ml PEBCA materials; equivalent amount of empty PEBCA NPs were given for comparison.
  • Left column Cell viability measured with the MTT assay after incubation for 72 h.
  • Right column Cell proliferation measured as [ 3 H]thymidine incorporation after incubation for 24 h.
  • FIG. 11 Treatment effects of a prostate carcinoma tumor model (PC3) with CBZ formulated as Jevtana®, CBZ in PEBCA NPs and control. Plots of mean tumor size in the three groups. Arrows show treatment days, error bars show standard deviation and *** indicates p>0.001, t-test.
  • nanoparticle, (NP) is used herein to describe particles or capsules with linear dimensions less than 800 nm.
  • PEGylation is used herein to describe the process of both covalent and non-covalent attachment or amalgamation of polyethylene glycol (PEG) polymer chains to nanoparticles, which is then described as PEGylated (pegylated).
  • PEG polyethylene glycol
  • pegylated polyethylene glycolated
  • the association of PEG to the NP surface can “mask” the NP from the host's immune system by creating a water corona around the NP. This can reduce the immunogenicity and antigenicity of the NP, and prolong its circulatory time by reducing renal clearance.
  • the PEG is classified as being in a brush or mushroom conformation.
  • the PEGylation can be performed either during or after synthesis of the NPs, by either a covalent or noncovalent bond, resulting in varying properties of the PEGylation.
  • targeting moiety is used herein to describe any molecule that can be bound to the surface of the NP and result in selective binding to specific cells or biological surfaces.
  • Passive targeting is used herein to describe the accumulation and/or retention of nanoparticles in inflamed and malignant tissue that occurs due to leaky blood vessels and impaired lymphatic drainage. Passive targeting is independent of targeting moieties on the surface of NPs.
  • active targeting is used herein to describe the accumulation and/or retention of the nanoparticle on specific cells or biological surfaces due to the specific interaction between the targeting moiety and the cell surface or the biological surface.
  • the term “enhanced permeability and retention (EPR)” effect is used herein to describe the phenomenon where molecules of certain sizes (typically liposomes, nanoparticles, and macromolecular drugs) tend to accumulate in tumor tissue much more than they do in normal tissues.
  • the NPs as described herein are typically of a size from about 1-800 nm, such as about 10-500, preferably about 70-150 nm. Accordingly, the EPR effect will allow the NPs as described herein to selectively extravasate and accumulate in tumors.
  • parenteral administration and “administered parenterally” are art recognized terms, and include modes of administration other than enteral and topical administration, such as injections, and include without limitation intravenous, intramuscular, intrapleural, intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
  • pharmaceutically acceptable denotes that the system or composition is suitable for administration to a subject, including a human patient, to achieve the treatments described herein, without unduly deleterious side effects in light of the severity of the disease and necessity of the treatment.
  • the terms “therapy”, “treat,” “treating,” and “treatment” are used synonymously to refer to any action providing a benefit to a patient at risk for or afflicted with a disease, including improvement in the condition through lessening, inhibition, suppression or elimination of at least one symptom, delay in progression of the disease, prevention, delay in or inhibition of the likelihood of the onset of the disease, etc.
  • microbubble associated with nanoparticles or “nanoparticles associated with microbubbles” are used herein to describe in what way nanoparticles can interact with the microbubble interface.
  • association with as used in connection with this include association by any type of chemical bonding, such as covalent bonding, non-covalent bonding, hydrogen bonding, ionic bonding or any other surface-surface interactions.
  • the present invention describes a drug delivery system comprising PEGylated poly (alkyl cyanoacrylate) (PACA) nanoparticles (NPs) loaded with cabazitaxel (CBZ) for use in treatment of cancer, provided that the drug delivery system does not comprise microbubbles (MBs).
  • PEGylated poly (alkyl cyanoacrylate) (PACA) nanoparticles (NPs) loaded with cabazitaxel (CBZ) for use in treatment of cancer, provided that the drug delivery system does not comprise microbubbles (MBs).
  • the effect of PACA NPs loaded with the cytotoxic drug CBZ is demonstrated in several in vitro and in vivo studies. As disclosed herein, the studies include demonstration of effects in three breast cancer cell lines, one basal-like patient-derived xenograft model grown in the mammary fat pad of immunodeficient mice and one prostate carcinoma tumor model. It is demonstrated that NP-encapsulated CBZ has similar or even better efficacy than similar concentrations of non-encapsulated drug. As demonstrated in the basal-like patient-derived xenograft, the results show complete remission of 6 out of 8 tumors.
  • the different drug concentrations obtained with NP-encapsulated versus non-encapsulated CBZ was investigated with mass spectrometry analyses of CBZ, which was performed using blood and selected tissue samples.
  • the results show that the nanoparticle-encapsulated drug has a longer circulation time in blood and a higher content in tumor tissue.
  • the tissue biodistribution which is obtained after 24 h using mass spectrometry analyses, correlates well with biodistribution data obtained using IVIS® Spectrum in vivo imaging of nanoparticles labeled with the fluorescent substance NR668. This is a clear indication that these data also are representative for the nanoparticle distribution.
  • the invention as disclosed herein is different form the drug delivery system as described in Snipstad et al (2017).
  • the drug delivery system of the invention does not comprise NP-stabilized MBs, as is described by Snipstad et al, 2017.
  • the drug delivery system according to the invention does not comprise NPs that stabilize the MBs nor NPs that are used to stabilize gas-filled MBs. Accordingly, the drug delivery system of the invention is not dependent on ultrasound to achieve treatments effects, in contrast to the delivery system described in Snipstad et al 2017, which is ultrasound-mediated.
  • one embodiment of the invention as provided herein is a drug delivery system comprising PEGylated PACA NPs loaded with CBZ, or a pharmaceutically acceptable salt thereof, for use in treatment of cancer, provided that the drug delivery system is not mediated by an acoustic field, such as ultrasound or focused ultrasound.
  • an acoustic field such as ultrasound or focused ultrasound.
  • the drug delivery system does not comprise NPs that are associated with the MB. It is also disclosed a drug delivery system that does not comprise gas-filled MBs. In yet a further embodiment, the drug delivery system does not comprise MBs.
  • Degradation rate of PACA NPs can be controlled by the choice of the alkyl chain of the cyanoacrylate monomer, as demonstrated by Sulheim et al. (2016). It has also been demonstrated, using a panel of cell lines, that the cytotoxicity is dependent on the monomers used, i.e. n-butyl-, 2-ethyl-butyl-, or octyl cyanoacrylate (BCA, EBCA and OCA, respectively), see Sulheim et al (2017).
  • the alkyl chain of the cyanoacrylate monomer is a linear or branched C4-C10 alkyl chain.
  • the monomer used is selected from the group consisting of n-butyl-(BCA), 2-ethyl butyl (EBCA), polyisohexyl (IHCA) and octyl cyanoacrylate (OCA).
  • the drug delivery system comprises NPs selected from the group consisting of PBCA, PEBCA, PIHCA and POCA.
  • the NPs are PEGylated, i.e. coated with a hydrophilic polymer such as polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • NPs by varying the type of PEG one can achieve NPs with different surface modifications. This will influence the zeta potential, the protein adsorption, diffusion, cellular interaction and blood circulation half-life of the NPs described herein.
  • the NPs are PEGylated with PEG-comprising molecules selected from the group consisting of Jeffamine, Brij, Kolliphor, Pluronic or combinations thereof.
  • the NPs are PEGylated with the PEG-comprising molecules selected from Pluronic and Kolliphor.
  • the NPs are PEGylated with the PEG-comprising molecules selected from Brij and Kolliphor.
  • the PACA NPs is produced by a miniemulsion anionic polymerization process, in particular a one-step process as described in WO2014/191502, both with or without targeting moieties.
  • NPs that is further surface modified with targeting moieties for example by using NPs prepared by miniemulsion anionic polymerization technique with polyalkylene glycols that is covalently attached to a targeting moiety, one can enable active targeting and potentially enhanced retention at specific locations, such as in tumors or diseased tissue. Also, this can facilitate uptake in cancer cells that is dependent upon specific ligand-receptor interactions.
  • the targeting moiety may be any suitable moiety that causes the NPs to bind specifically at targeted locations.
  • the targeting moiety has a molecular weight in the range 100 to 200 000 Da, more preferably 200 to 50000 Da, even more preferably 300 to 15000 Da.
  • Example targeting moieties are selected from the group consisting of an amino acid, protein, peptide, antibody, antibody fragment, saccharide, carbohydrate, glycan, cytokine, chemokine, nucleotide, lectin, lipid, receptor, steroid, neurotransmitter, cell surface marker, cancer antigen, glycoprotein antigen, aptamer or mixtures thereof.
  • Particularly preferred targeting moieties include linear and cyclic peptides. In one embodiment, the targeting moiety does not belong to the group consisting of amino acids and lipids
  • EPR enhanced permeability and retention
  • tumor targeting approaches are classified into ‘passive targeting’ and ‘active targeting’.
  • the EPR effect will be known to the skilled person as a form of passive targeting.
  • the introduction of targeting moieties on the surface of the NP will be known to the skilled person as a type of active targeting.
  • Angiogenesis is a biological process by which new capillaries are formed. It is essential in many physiological conditions, such as embryo development, ovulation and wound repair, and pathological conditions, such as arthritis, diabetic retinopathy, and tumors.
  • Tumors can grow to a size of approximately 1-2 mm 3 before their metabolic demands are restricted due to the diffusion limit of oxygen and nutrients. In order to grow beyond this size, the tumor switches to an angiogenic phenotype and initiates the formation of neovasculature from surrounding blood vessels. Accordingly, tumors are endowed with angiogenic capability and their growth, invasion and metastasis are angiogenesis-dependent. Apart from some exemptions, in most cases, neoplastic cell populations will form a clinically observable tumor only after angiogenic capability has been acquired and a vascular network sufficient to sustain their growth is produced. Furthermore, new blood vessels provide them with a gateway through which they enter the circulation and metastasize to distant sites. Tumor angiogenesis is essentially mediated by angiogenic molecules elaborated by tumor cells.
  • VEGF Vascular endothelial growth factor
  • other growth factors known to the skilled person, are involved in cancer angiogenesis. Tumor cell aggregates as small as 150-200 ⁇ m, will start to become dependent on blood supply carried out by neovasculature for their nutritional and oxygen supply.
  • these newly formed tumor vessels are usually abnormal in form and architecture. They have poorly aligned defective endothelial cells with fenestrations, lacking a smooth muscle layer, or innervation with a wider lumen, and impaired functional receptors for angiotensin II.
  • tumor tissues usually lack effective lymphatic drainage. All of these factors lead to abnormal molecular and fluid transport dynamics, especially suitable for NPs as disclosed herein.
  • the EPR effect will results in passive accumulation of NPs in tumors due to the hyperpermeability of the vasculature and the lack of lymphatic drainage. This is contrary to what is seen in normal tissue where the NPs are constrained to the blood vessels. This makes the NPs as described herein attractive for tumor targeting.
  • the systemic circulation time of the NPs are increased. By extending the circulation time, an enhanced number of NPs will be able to accumulate in the tumors, as it increases the probability for the NPs to diffuse through openings in the blood vessels.
  • the drug delivery system is for treatment of cancer, such as tumors, including but not limited to tumors of the colon, lung, breast, cervix, bladder, prostate and pancreas.
  • cancer such as tumors, including but not limited to tumors of the colon, lung, breast, cervix, bladder, prostate and pancreas.
  • the NPs according to the invention partly accumulate in the lymph nodes. This may be utilized to treat metastasizing cancer cells in lymph nodes.
  • the drug delivery system is for treating metastasizing cancer cells in lymph nodes.
  • the drug delivery system is for prophylactic treatment of cancer by preventing metastasis through the lymph nodes.
  • the drug delivery system is for treatment of tumors and for prophylactic treatment of metastasis.
  • the tumor has vasculature that is hyperpermeable and/or lack lymphatic drainage.
  • Tumor growth consists of an avascular and a subsequent vascular phase.
  • the tumor is in a vascular phase.
  • CBZ cytotoxic drug cabazitaxel
  • CBZ is a semi-synthetic taxane derivative that inhibits microtubule disassembly.
  • CBZ has a very low water solubility, which complicates the administration of the free, non-encapsulated drug.
  • the loading capacity of CBZ in NPs can be 1-90 wt % of the NP, preferentially 5-50 wt % of the NP.
  • the loading capacity of CBZ is from 5-15 wt % of the NP, such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 wt % of the NP.
  • the drug delivery system according to the invention has a high loading capacity, which is shown to influence the treatment effects of the invention.
  • the conventional formulation is CBZ solubilized in a polysorbate 80 solution.
  • non-encapsulated or free CBZ refers to the conventional formulation.
  • CBZ has been included in several clinical trials that study the effects on different types of cancer including several types of prostate cancer, adrenocortical carcinoma, testicular cancer, urothelium transitional cell carcinoma and ovarian cancer.
  • the inventors have also demonstrated therapeutic effects of CBZ in glioma and lung cancer.
  • the advantage that drug-loaded NPs give less adverse effects than free drug makes the drug delivery system as described by the inventors highly relevant for CBZ.
  • Encapsulating CBZ in NPs offers a more sustained release profile of the drug, which can ameliorate parts of the toxicity and allows for administration of higher doses.
  • the reduction of adverse effects allows for administration of increased doses of drugs.
  • encapsulation of drug in the NPs will further improve the treatment effects.
  • the inventors propose the idea that the drug delivery system as described herein will enhance treatments effects and/or reduce side effects when used in treatment of cancer.
  • the invention provides a drug delivery system comprising PEGylated PACA NPs loaded with CBZ, or a pharmaceutically acceptable salt thereof, for use in treatment cancer, wherein the tumors belong to a type of cancer selected from the group consisting of prostate cancer, breast cancer, glioma, lung cancer, adrenocortical carcinoma, testicular cancer, urothelium transitional cell carcinoma and ovarian cancer.
  • the tumor belongs to a type of prostate cancer, such as prostate carcinoma, hormone refractory prostate cancer, prostatic neoplasms or bone metastatic prostate cancer.
  • the tumor belongs to a type of breast cancer, including luminal-like and basal-like breast cancer.
  • Breast cancer can be classified into major subgroups based on the gene expression pattern. Tumors belonging to the most aggressive subtypes are commonly treated with antracyclin and taxane-based chemotherapy regimens.
  • the growth inhibitory effect of CBZ encapsulated into PEBCA NPs is demonstrated in breast cancer models in vitro and in vivo, and in a prostate carcinoma tumor model in vivo.
  • Three breast cancer cell lines representing the two main types of breast cancer, the luminal and basal-like subgroups was used.
  • One of the cell lines is also injected and grown in the mammary fat pad of immunodeficient mice.
  • PDX patient-derived xenograft
  • the examples demonstrate in vivo biodistribution of particles loaded with the lipophilic and near-infrared fluorescent substance NR668. Quantitative mass spectrometry analyses were used to describe the biodistribution of CBZ in tissues and the kinetics of CBZ in blood plasma after injection of both PEBCA-CBZ and non-encapsulated CBZ.
  • the example with prostate carcinoma demonstrates that the CBZ encapsulated into PEBCA NPs had similar growth inhibition as the clinically approved formulation.
  • the drug delivery system of the present invention allows for administration of higher dosage with lower adverse effects.
  • lymph nodes have been discussed for treatment of metastasizing tumors. Since local lymph nodes are a significant metastatic site in many cancer types, accumulation of PEBCA-CBZ to lymphatic tissue may contribute additionally to both therapeutic and prophylactic treatment.
  • the PEBCA-CBZ NPs demonstrate promising results for treatment of prostate cancer and breast cancer, supporting the therapeutic effect of a drug delivery system for use in treatment of tumors as disclosed herein.
  • the drug delivery system is provided in a composition to be administered systemically, such as parenterally.
  • a last aspect of the invention includes a method of treating cancer comprising administering a drug delivery system according to the first aspect of the invention to a patient in need thereof.
  • PEGylated PEBCA NPs were synthesized by miniemulsion polymerization.
  • An oil phase consisting of 2.5 g 2-ethylbutyl cyanoacrylate (monomer, Cuantum Medical Cosmetics, Spain) containing 0.2% (w/w) butylated hydroxytoluene (Fluka, Switzerland) and 2% (w/w) Miglyol 812 (Cremer, USA) was prepared.
  • Fluorescent particles for optical imaging were prepared by adding NR668 (modified Nile Red), custom synthesis, 0.2% (w/w) to the oil phase.
  • Particles containing cytostatic drug for treatment were prepared by adding CBZ (10% (w/w), Biochempartner Co. Ltd., China, product item number BCP02404) to the oil phase.
  • aqueous phase consisting of 0.1 M HCl (20 ml) containing Pluronic F68 (2 mM, Sigma, USA) and Kolliphor HS15 (6 mM, Sigma, Germany) was added to the oil phase and immediately sonicated for 3 min on ice (6 ⁇ 30 sec intervals, 60% amplitude, Branson Ultrasonics digital sonifier 450, USA).
  • the solution was rotated (15 rpm, SB3 rotator, Stuart, UK) at room temperature overnight before adjusting the pH to 5 using 1 M NaOH.
  • the polymerization was continued for 5 h at room temperature on rotation.
  • the dispersion was dialyzed (Spectra/Por dialysis membrane MWCO 100,000 Da, Spectrum Labs, USA) against 1mM HCl to remove unreacted PEG.
  • the size, polydispersity index (PDI) and the zeta potential of the NPs were measured by dynamic light scattering and laser Doppler Micro-electrophoresis using a Zetasizer Nano ZS (Malvern Instruments, UK).
  • PDI polydispersity index
  • zeta potential of the NPs were measured by dynamic light scattering and laser Doppler Micro-electrophoresis using a Zetasizer Nano ZS (Malvern Instruments, UK).
  • the drug was extracted from the particles by dissolving them in acetone (1:10), and quantified by liquid chromatography coupled to mass spectrometry (LC-MS/MS) as described below.
  • CBZ quantification by LC-MS/MS was quantified by LC-MS/MS, using an Agilent 1290 HPLC system coupled to an Agilent 6490 triple quadrupole mass spectrometer.
  • the HPLC column was an Ascentis Express C8, 75 ⁇ 2.1 mm, 2.7 ⁇ m particles size with a 5 ⁇ 2.1 mm guard column of the same material (Sigma), run at 40° C.
  • Eluent A was 25 mM formic acid in water and eluent B was 100% methanol, and flow rate was 0.5 ml/min.
  • the mobile phase gradient was isocratic at 55% B for 1.5 min, then from 55% to 80% B over 1 min, followed by 1 min washout time and subsequently column re-equilibration. Injection volume was 5.00 ⁇ l.
  • MS detection was in positive ESI mode (Agilent Jetstream) quantified in multiple reaction monitoring (MRM) mode using the transition m/z 858.3 ⁇ 577.2. The parent ion was chosen to be the Na adduct as this gave the best sensitivity.
  • MRM multiple reaction monitoring
  • the parent ion was chosen to be the Na adduct as this gave the best sensitivity.
  • the hexadeuterated internal standard was detected on the 864.4 ⁇ 583.2 transition. Both analytes were run at 380 V fragmentor and 20 V collision energy.
  • the limit of quantification was calculated from six replicate quantifications of the lowest concentration point in the standard curves (0.1 ng/ml), specifically as the average plus six standard deviations; this amounted to an LOQ of 0.19 ng/ml (signal/noise ratio >20). Accuracy based on the same standard sample set was 8.8% and precision was 18.0%.
  • the enzyme buffer consisted of Dulbecco's Modified Eagle Medium (DMEM, Thermo Fisher Scientific, USA, 41965039) with 1% (v/v) penicillin-streptomycin stock solution (Sigma-Aldrich, P0781) to a final concentration of 100 U/ml penicillin and 100 ⁇ g/ml streptomycin, 0.125 mg/ml papain (Merck, F275644), 2.5 mg/ml trypsin (Sigma-Aldrich, T7409), 0.8 mg/ml collagenase (Sigma-Aldrich, C7926), 0.69 mg/ml hyaluronidase (Sigma-Aldrich, H3506) and 1% (v/v) Triton X-100 (Sigma-Aldrich, T-8787).
  • DMEM Dulbecco's Modified Eagle Medium
  • P0781 penicillin-streptomycin stock solution
  • P0781 penicillin-streptomycin stock
  • MDA-MB-231 triple negative; Claudin low
  • MDA-MB-468 triple negative; basal
  • MCF-7 luminal A
  • All medium was fortified with 10% (w/v) fetal calf serum albumin (Sigma) and 100 units/ml penicillin/streptomycin (PenStrep®, Sigma). All cell lines were obtained from ATCC and were routinely tested for mycoplasma.
  • MTT cell viability assay The cells were incubated for 24, 48 and 72 h with the different NPs/substances. The cell medium was then aspirated and exchanged with 100 ⁇ l of medium containing a final concentration of 250 ⁇ g MTT/ml. The incubation was continued for 3 h at 37° C. for formation of the formazan-particles, which were dissolved in DMSO with 1% (v/v) NH 4 Cl. The absorbance was read in a plate reader (Biosys Ltd, Essex, UK) at 570 nm, and background from absorbance at 650 nm was subtracted.
  • mice Treatment efficacy evaluation in nude mice. All animal experiments were approved and performed according to the Norwegian Animal Research Authority (Permit number 15-136041) and were conducted according to the regulations of the Federation of European Laboratory Animal Science Association (FELASA). The mice were kept under pathogen-free conditions, at constant temperature (21.5 ⁇ 0.5° C.) and humidity (55 ⁇ 5%); 15 air changes/h and a 12 h light/dark cycle. They had access to distilled water ad libitum, which was supplemented with 17- ⁇ -estradiol at a concentration of 4 mg/l. All mice used in this study were female athymic nude foxn1 nu mice (age 5-6 weeks and body weights of 18-20 g), locally bred at the Department of Comparative Medicine, Oslo University Hospital, Norway.
  • FELASA European Laboratory Animal Science Association
  • the ortothopically growing basal-like xenograft model MAS98.12 has been established in house and was used as previously described in Lindholm et al (2012).
  • 1.5 million cells were injected into the mammary fat pad and growing tumors were used for sequential implantation.
  • the MAS98.12 model 1-2 mm 3 pieces of healthy tumor tissue were implanted bilaterally into the mammary fat pad of female athymic mice. After the tumors reached approximately 5 mm in diameter, the mice were randomly assigned to the different treatment groups (the average volume of each group was 49-57 mm 3 ).
  • Non-encapsulated CBZ was prepared as a stock solution in Polysorbate 80 (40 mg/ml) and further diluted with 13% (v/v) ethanol to a working solution of 10 mg/ml CBZ.
  • the injection solution was prepared directly before the administration by dilution of the working solution with 0.9% (w/v) NaCl.
  • ethanol (1.2-1.4% (v/v)
  • injection volumes were in the range 200-290 ⁇ l.
  • tumor diameter and body weight were measured twice weekly. Mice were monitored daily for health status and were killed by cervical dislocation if they became moribund or if tumor reached 1500 mm 3 .
  • the tumor was measured by calipers and the tumor volume was calculated according to the formula 0.5 ⁇ length ⁇ width and related to the mean tumor volume at start of treatment.
  • PEBCA NPs labeled with the lipophilic and fluorescent dye NR668 were used to study the biodistribution in MA98.12 bearing mice using an IVIS® Spectrum in vivo imaging system (Perkin Elmer). Mice were intravenously injected the same dose PEBCA-CBZ or PEBCA without drug as in the efficacy study. The batch containing CBZ has somewhat larger particles than the batch not containing CBZ (Table 51). The excitation/emission wavelength pair of 535/640 nm was found to give the best signal-to-noise ratio and was thus used for imaging of the NPs. Whole body images were obtained 1, 4, 24 and 96 h after injection; the animals were then sacrificed by cervical dislocation and organs were harvested.
  • the organs were imaged ex vivo with the IVIS scanner using the same settings as above. Relative signal intensity in the organs was calculated, using Living Image software (Perkin Elmer), as radiant efficiency (Emission light [photons/sec/cm 2 /str]/Excitation light [ ⁇ W/cm 2 ] ⁇ 10 9 ) per pixel of the region of interest, which was drawn around the respective organ. Fluorescent measurements of the PEBCA NPs used for in vivo imaging showed that the particles without CBZ had a fluorescent intensity of 1.17 times that of the PEBCA NPs containing CBZ and the data shown in FIG. 3C are corrected for this difference.
  • the blood was centrifuged for 15 min at 4° C. and 3400 ⁇ g, and the supernatant plasma was collected and stored at ⁇ 80° C. until LC-MS/MS analysis.
  • the animals were killed after 24 or 96 h and tissue samples (tumors, livers, spleens, lymph nodes and kidneys) were harvested. The organs were gently washed with saline and then snap frozen in liquid nitrogen and stored at ⁇ 80° C. until further processing and LC-MS/MS analyses as described above. Statistical analyses were performed using the t-test.
  • Tumors from MAS98.12 bearing mice were collected 96 h after a single injection of the same substances as were injected in the MAS98.12 efficacy study.
  • the tumors were preserved in 4% (v/v) formalin and then paraffinized and sliced to prepare consecutive slides (3 ⁇ m thick).
  • the deparaffinization agent Neo-clear and mounting agent Neo-mount were obtained from VWR (Radnor, Pa., USA). Heat induced epitope retrieval was performed by placing deparaffinized slides with 10 mM sodium citrate buffer (pH 6.0) in water bath for 20 min at 100° C.
  • anti-CD68 (1 mg/ml; ab125212, Abcam, Cambridge, UK), anti-CD206 (0.1 ⁇ g/ml; ab64693, Abcam, Cambridge, UK), and anti-iNOS (0.5 ⁇ g/ml; ab15323, Abcam, Cambridge, UK) were used to detect different population of macrophages.
  • CD68 is a commonly used marker for the whole macrophage population
  • iNOS inducible nitric oxide synthase
  • M1 macrophages anti-tumourigenic and pro-inflammatory macrophages
  • CD206 is a marker for M2 macrophages (pro-tumourigenic and anti-inflammatory macrophages).
  • TBS was used for washing the slides between steps.
  • Detection of primary antibodies was performed using MACH 3 rabbit HRP-polymer detection kit according to the manufacturer's protocol (Biocare Medical, Concord, Calif., USA). Signals were developed by incubation with the Chromogen solutions provided with the Betazoid DAB Chromogen kit (Biocare Medical). For counter staining a haematoxylin and 37 mM ammonium hydroxide containing solution (Sigma-Aldrich, St. Louis, Mo., USA) were used.
  • PEBCA particles Characterization of PEBCA particles.
  • the particle size, polydispersity index (PDI) and zeta potential for the batches used were in the range of 148-227 nm (z-average), 0.04-0.19 and ⁇ (0.6-2.4) mV, respectively.
  • the drug content in the final particles was 6.0-8.6% (w/w), giving 2.0-3.4 mg CBZ/ml in the NP stock solutions (Table S1).
  • the size of PEBCA NPs increased when adding the drug CBZ or the fluorescent label NR668 (Table S1).
  • the size distribution curves for the two batches used for efficacy studies in the MAS98.12 tumor model and that of CBZ (forming clusters in solution) are shown in FIG. 1 .
  • PEBCA-CBZ inhibits tumor growth more efficiently than free CBZ in the MAS98.12 mice model.
  • MAS98.12 tumors were implanted into the mammary fat pad of nude mice and treated with the drug-loaded particles (PEBCA-CBZ), empty particles (PEBCA), non-encapsulated (free) CBZ and saline as control ( FIG. 2A ).
  • the injected dose was 2 ⁇ 15 mg CBZ/kg body weight, which corresponds to a particle dose of 2 ⁇ 175 mg/kg ( FIG. 2A ).
  • Tumor growth was not affected by empty PEBCA NPs.
  • PEBCA-CBZ and non-encapsulated CBZ were intravenously injected into the tail vein of mice bearing the MAS98.12 tumor. Blood samples were taken approximately 2 min after injection, and 1, 4, 24 and 96 h after injection, and the plasma samples were analyzed for CBZ using an LC-MS/MS method.
  • the CBZ concentrations at almost all time points were at least 10-fold higher in mice receiving PEBCA-CBZ compared to mice receiving free CBZ ( FIG. 4A ).
  • the plasma concentration/time curves for both PEBCA-CBZ and CBZ indicate an initial distribution phase, followed by a terminal elimination phase.
  • the CBZ concentrations were measured in tumor, liver, spleen, lymph nodes, and kidney following a single injection of PEBCA-CBZ and CBZ (15 mg/kg).
  • the results obtained with samples taken 24 and 96 h after injections are shown in FIGS. 4B and C, respectively.
  • the highest amount of drug per mg tissue was obtained in spleen.
  • the data in FIG. 4 indicates that the liver/spleen ratio of PEBCA-CBZ is 2.1 times 24 h after injection and 4.4 times 96 h after injection demonstrating that liver is taking up the largest part of these NPs.
  • the amounts of CBZ in the tumor samples measured as ng CBZ/mg tissue were 20% (24 h) and 1.4% (96 h) of that in liver after injection of PEBCA-CBZ.
  • CBZ concentration of CBZ was significantly higher (t-test; p-value ⁇ 0.01) in all tissues analyzed 24 h following injection of particle bound (PEBCA-CBZ) as compared to non-encapsulated drug (CBZ), with the largest differences observed in liver and spleen which contained the highest amounts of PEBCA-CBZ. Following injection of non-encapsulated CBZ, the highest concentration of CBZ was found in the tumor, although this level was only about 1 ⁇ 3 of that obtained in the PEBCA-CBZ group. In the samples obtained 96 h after injection, CBZ could be detected (i.e.
  • Macrophage infiltration in treated MAS98.12 tumors The infiltration of macrophages into the MAS98.12 tumors during treatment was estimated by immunohistochemistry. The extent of total population of infiltrating macrophages was quantified using an antibody against CD68 and automatic quantification of scanned slides. An increased level of tumor infiltrating macrophages was observed in mice injected PEBCA-CBZ or PEBCA without drug compared to mice receiving free CBZ or saline, but the differences did not reach statistical significance ( FIG. 5A ). Also the marker of pro-inflammatory M1 macrophages (iNOS) demonstrated increased macrophage infiltration into tumors of mice receiving PEBCA-CBZ or PEBCA ( FIG. 5B ).
  • iNOS marker of pro-inflammatory M1 macrophages
  • the anti-inflammatory M2 macrophages subset demonstrated increased infiltration compared to the saline control only in tumors receiving PEBCA ( FIG. 5C ). Furthermore, the tumors of mice receiving PEBCA-CBZ showed significant lower levels of this pro-tumorigenic macrophage population than tumors receiving PEBCA alone (p ⁇ 0.001; FIG. 5C ).
  • PEBCA-CBZ In vitro cell studies. We tested cellular toxicity of PEBCA-CBZ, non-encapsulated CBZ and PEBCA without drug in three cell lines, i.e. MDA-MB-231, MDA-MB-468 and MSF-7 using two different test systems, i.e. measuring cell proliferation by incorporation of [ 3 H]thymidine after 24 h and cell viability after 72 h using the MTT assay. PEBCA-CBZ and CBZ were significantly more toxic than PEBCA without drug for all cell lines (range 130-350 fold), but there was no difference in the toxic effect of PEBCA-CBZ and CBZ in any of these test systems in any cell line ( FIG. 10 ).
  • the MTT assay was also performed on MDA-MB-231 cells after 24 and 48 h of incubation; the data obtained were similar to those shown after 72 h of incubation ( FIG. 10 ), although the toxic effect was smaller after these shorter incubation times (data not shown).
  • the amount of CBZ was quantified in blood plasma and in several tissues using an LC-MS/MS method.
  • the plasma data clearly show CBZ to be circulating for a longer time when incorporated in the NPs, and the CBZ concentration was at least 10-fold higher at nearly all time points in mice receiving PEBCA-CBZ compared to those receiving free CBZ ( FIG. 4A ).
  • the CBZ incorporated in NPs does not have a therapeutic effect before being released from the NPs.
  • biodegradation of the NPs is necessary to obtain a good therapeutic effect, as exemplified in the MAS98.12 model.
  • the in vivo fluorescence imaging data obtained with PEBCA NPs labeled with NR668 demonstrates accumulation of the fluorescence in the same tissues as those where CBZ was found to be present. As expected these data show that most of the NPs end up in the liver.
  • the liver/spleen ratio of the fluorescence per pixel measured 24 h after injection was estimated to be 2.9 for NPs without CBZ and 2.4 for NPs with CBZ, whereas the ratio of total CBZ content in liver to spleen was calculated to 2.1 based on the MS analyses.
  • the mean fluorescent signal obtained in the tumors 24 h after injection was 12% of that in liver for the NPs not containing CBZ and 3% for the NPs containing CBZ.
  • the IVIS data ( FIGS. 3A , B) indicate higher fluorescence following injection of PEBCA NPs without drug than for NPs containing CBZ. Perhaps the somewhat larger size of the NPs with drug (Table S1) contributes to this difference.
  • Macrophages are the most abundant immune cells in mammary tumors.
  • Tumor associated macrophages TAMs
  • the pro-tumorigenic macrophages are known as alternatively activated and referred to as anti-inflammatory (M2-type), whereas the classically activated pro-inflammatory (M1-type) macrophages exhibit anti-tumorigenic properties.
  • Plasticity is a hallmark of the macrophage population and dynamic changes in their phenotype define the different subtypes.
  • Markers of M1 and M2 are commonly used to recognize the main phenotypes or functions, but a set of markers is recommended for a more comprehensive characterization of the whole population.
  • the well accepted nitric oxide synthase (iNOS) have been used for detection of the M1 phenotype and mannose receptor (CD206) to define the M2-type.
  • the TAMs are influenced by the context, e.g. by factors in the microenvironment or externally added anticancer drugs.
  • the effect of docetaxel has been shown to partly depend upon depletion of M2 macrophages and expansion of M1 macrophages in models of breast cancer.
  • no response in the macrophage populations upon treatment with free CBZ, another taxane was observed, despite efficient growth retardation.
  • treatment with PEBCA encapsulated CBZ resulted in significant improved anti-tumor efficacy, and complete remission in 75% of the tumors. Even though the number of tumors used for immunohistochemical quantification is small, the data suggest two possible mechanisms that may explain this good effect.
  • PEBCA NPs a trend towards elevated inflammation in tumors upon treatment with PEBCA NPs (with or without drug) was observed. This may imply a role of PEBCA NPs in homing anti-tumorigenic M1 macrophages into the tumors and thus further support the effect of CBZ.
  • PEBCA-CBZ treatment significantly reduced CD206 expression in tumors compared to treatment with NPs without drug, which may point towards depletion of pro-tumorigenic macrophages.
  • M2 macrophages show a vigorous endocytic uptake by macropinocytosis, whereas this uptake was virtually inactive in the M1 macrophages. Furthermore, another study showed that the M2 macrophages use endocytosis to degrade collagen and promote tumor growth in solid tumors. Without being bound by theory, the decrease in M2 macrophages observed after treatment with PEBCA-CBZ and the strong effect on the tumor growth is related to the macropinocytic uptake of PEBCA-CBZ and subsequent killing of these M2 macrophages. Thus, the inherent properties of M1 and M2 macrophages and selective toxic effect of drug containing particles on M2 macrophages may increase the efficacy of the treatment. It has earlier been published that driving TAMs toward M1 polarization (increasing the ratio of M1/M2 macrophages) has shown promising therapeutic effects in mice cancer models.
  • the tumor vasculature is a critical factor for the accumulation of NPs in tumor. It is shown earlier that the basal-like MAS98.12 tumor has a higher vascularization than the luminal-like MAS98.06 tumor. Although angiogenesis also has been visualized in MDA-MB-231 tumors in mice, the difference in vascularization of the MAS98.12 and MDA-MB-231 tumors is less well characterized. However, in two previously published studies, the blood volume constituted 2.4% of the tumor volume 5 weeks after inoculation of MDA-MB-231 and 5.9% at 5 weeks after transplantation of MAS98.12, suggesting more efficient vascularization in the latter model. Accordingly, the degree of vascularization may influence the efficacy.
  • NPs were shown to rapidly release vincristine and vincristine also accumulated in lymph nodes following injection of the non-encapsulated drug, it is difficult to evaluate to which extent these NPs actually accumulated in the lymph nodes. Delivery of drug to lymph nodes has been discussed for treatment of metastasizing tumors. Since local lymph nodes are the first site of locoregional breast cancer metastasis, and also a significant metastatic site in the aggressive triple negative basal like breast cancer, accumulation of PEBCA-CBZ to lymphatic tissue may contribute additionally to such treatment.
  • the PEBCA-CBZ NPs demonstrate promising results for treatment of breast cancer, supporting the therapeutic effect of a drug delivery system for use in treatment of solid tumors as disclosed herein.
  • Jevtana was formulated as described in the treatment study on breast cancer. Briefly, CBZ was dissolved to 40 mg/ml in Tween, 80, then diluted 1:4 in 13% EtOH. CBZ-loaded PEBCA NPs was prepared and characterized as described in the breast cancer treatment study. Briefly, CBZ was added to the monomer phase at 10% w/v and the pegylated PEBCA NPs were made in a one step miniemulsion polymerization. The NPs were characterized for size, size distribution and zeta-potential with DLS.
  • Human PC3 prostate adenocarcinoma cells were grown in DMEM with 10% FBS and 1% Pencillin/streptavidin. 3 million cells in 50 ⁇ l cell medium were injected subcutaneously on the hind leg of the mouse. When the tumor reached a volume of 200 mm 3 , treatment was started and the continued with one treatment weekly for three weeks. The animals were randomly distributed into three groups receiving: 1; control—no treatment, 2; 10 mg/kg CBZ-PEBCA, 3; 10 mg/kg Jevtana. The drugs were administered through a catheter in the tail vein. The tumors were measured twice weekly using a caliper and the animals were euthanized when tumors reached 1000 mm 3 .
  • the NPs were characterized with dynamic light scattering, and had a diameter of 180 nm, PDI of 0.18 and zeta-potential of ⁇ 1.7 mV. CBZ-encapsulation was measured with mass spectrometry and was found to be 8.5% w/w of the NP mass.
  • CBZ had a similar growth inhibition when formulated either as the clinical approved formulation or in PEBCA NPs ( FIG. 1 ). Both treatments were significantly different (p ⁇ 0.001, t-test) from the untreated control 14 days after the first treatment.
  • FIG. 11 mean tumor size in the three groups are plotted. Arrows show treatment days, error bars show standard deviation and *** indicates p>0.001, t-test. As can be seen from the figure, the cytostatic effects of CBZ formulated in PEBCA NPs was similar to the effects of the clinical formulation of the drug in the prostate cancer model PC3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US17/041,094 2018-03-27 2019-03-27 Poly (Alkyl Cyanoacrylate) Nanoparticles for Use in Treatment of Cancer Pending US20210113482A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20180429 2018-03-27
NO20180429 2018-03-27
PCT/EP2019/057678 WO2019185685A1 (en) 2018-03-27 2019-03-27 Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer

Publications (1)

Publication Number Publication Date
US20210113482A1 true US20210113482A1 (en) 2021-04-22

Family

ID=66049182

Family Applications (3)

Application Number Title Priority Date Filing Date
US17/041,094 Pending US20210113482A1 (en) 2018-03-27 2019-03-27 Poly (Alkyl Cyanoacrylate) Nanoparticles for Use in Treatment of Cancer
US16/366,596 Active US11806330B2 (en) 2018-03-27 2019-03-27 PACA and cabazitaxel for anti-cancer treatment
US16/583,687 Abandoned US20200061019A1 (en) 2018-03-27 2019-11-12 Drug delivery system for treatment of cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/366,596 Active US11806330B2 (en) 2018-03-27 2019-03-27 PACA and cabazitaxel for anti-cancer treatment
US16/583,687 Abandoned US20200061019A1 (en) 2018-03-27 2019-11-12 Drug delivery system for treatment of cancer

Country Status (8)

Country Link
US (3) US20210113482A1 (pt)
EP (2) EP3773471A1 (pt)
JP (2) JP7317038B2 (pt)
CN (2) CN111989087A (pt)
AU (1) AU2019437385A1 (pt)
BR (2) BR112020019452A2 (pt)
CA (1) CA3134923A1 (pt)
WO (2) WO2019185685A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806330B2 (en) 2018-03-27 2023-11-07 Sintef Tto As PACA and cabazitaxel for anti-cancer treatment

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957793B2 (en) * 2018-08-23 2024-04-16 Sintef Tto As Nanoparticles
CA3172776A1 (en) * 2020-02-26 2021-09-02 Biosergen As Pharmaceutical compositions of a therapeutic polyene macrolide and methods of their use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016020A2 (fr) * 2004-07-07 2006-02-16 Ethypharm Nanoparticules comprenant un coeur constitue essentiellement d’un polymere cyanoacrylique et une ecorce d’un polymere amphiphile, et eventuellement un principe actif qui est preferablement du busulfan
US20080182776A1 (en) * 2007-01-31 2008-07-31 Tong Shen Enterprise Co., Ltd. Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process foe the preparation thereof
US20100015165A1 (en) * 2006-07-04 2010-01-21 Katharina Landfester Two Step Miniemulsion Process
WO2014191502A1 (en) * 2013-05-28 2014-12-04 Sinvent As Process for preparing stealth nanoparticles
US20190298682A1 (en) * 2018-03-27 2019-10-03 Sintef Tto As Paca and cabazitaxel for anti-cancer treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2609268A1 (en) 2005-05-23 2006-11-30 University Of Utah Research Foundation Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents
FR2921660B1 (fr) 2007-10-01 2015-09-25 Centre Nat Rech Scient Nanoparticules hybrides organiques inorganiques a base de carboxylates de fer.
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
EP2508207B1 (en) * 2011-03-31 2013-05-08 BioAlliance Pharma Nanoparticles loaded with chemotherapeutic antitumoral Drug
US20150343079A1 (en) 2012-10-25 2015-12-03 Sogang University Research Foundation Ultrasound contrast agent with nanoparticles including drug and method for preparing the same
US10391185B2 (en) 2014-11-26 2019-08-27 Fujifilm Visualsonics, Inc. Multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles
WO2016134115A1 (en) 2015-02-20 2016-08-25 Trustees Of Boston University Theranostic compositions and uses thereof
EP3316871A4 (en) * 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF
US10980826B2 (en) * 2015-11-06 2021-04-20 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
EP3909983A1 (en) * 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
US11351125B2 (en) 2016-02-24 2022-06-07 Xuanwu Hospital Of Capital Medical University Poly(n-butyl cyanoacrylate) nanoparticle with dual modifications, preparation method and use thereof
WO2017204475A1 (ko) 2016-05-24 2017-11-30 한양대학교 산학협력단 항암제 함유 나노입자를 포함하는 뇌질환 치료를 위한 비강 투여용 약제학적 조성물
CA3040016A1 (en) 2016-09-29 2018-04-05 Sintef Tto As A new drug delivery system for treatment of disease
NO342271B1 (en) * 2016-09-29 2018-04-30 Sintef Tto As A new drug delivery system for treatment of cancer
US20220257525A1 (en) 2019-03-27 2022-08-18 Sintef Tto As Drug delivery system for treatment of cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016020A2 (fr) * 2004-07-07 2006-02-16 Ethypharm Nanoparticules comprenant un coeur constitue essentiellement d’un polymere cyanoacrylique et une ecorce d’un polymere amphiphile, et eventuellement un principe actif qui est preferablement du busulfan
US20100015165A1 (en) * 2006-07-04 2010-01-21 Katharina Landfester Two Step Miniemulsion Process
US20080182776A1 (en) * 2007-01-31 2008-07-31 Tong Shen Enterprise Co., Ltd. Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process foe the preparation thereof
WO2014191502A1 (en) * 2013-05-28 2014-12-04 Sinvent As Process for preparing stealth nanoparticles
US20160129132A1 (en) * 2013-05-28 2016-05-12 Sinvent As Process for Preparing Stealth Nanoparticles
US20190298682A1 (en) * 2018-03-27 2019-10-03 Sintef Tto As Paca and cabazitaxel for anti-cancer treatment
US11806330B2 (en) * 2018-03-27 2023-11-07 Sintef Tto As PACA and cabazitaxel for anti-cancer treatment

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Diéras et al.; "Cabazitaxel in patients with advanced solid tumors: Results of Phase I and pharmacokinetic study," 2013, ELSEVIER; European Journal of Cancer, Vol. 49, pp. 25-34. (Year: 2013) *
Hekmatara et al.; "Encapsulation of Water-Insoluble Drugs in Poly(butyl cyanoacrylate) Nanoparticles," 2009; ASP; Journal of Nanoscience and Nanotechnology, Vol. 9, pp. 5091-5098. (Year: 2009) *
Hu et al.; "Docetaxel-Loaded Cholesterol-PEG Co-Modified Poly (n-Butyl) Cyanoacrylate Nanoparticles for Antitumor Drug Pulmonary Delivery: Preparation, Characterization, and in vivo Evaluation," 2020, Dovepress; International Journal of Nanomedicine, Vol. 15, pp. 5361-5376. (Year: 2002) *
Huang et al.; "Synthesis of high loading and encapsulation efficient paclitaxel-loaded poly(n-butyl cyanoacrylate) nanoparticles vi miniemulsion," 2007; ELSEVIER; International Journal of Pharmaceutics, Vol. 338, pp. 267-275. (Year: 2007) *
Kummari et al.; "Biodegradable polymeric nanoparticles based drug delivery systems," 2010; ELSEVIER; Colloids and Surfaces B: Biointerfaces, Vol. 75, pp. 1-18. (Year: 2010) *
Machine Translation of WO-2006/016020-A2, pp. 1-13. (Year: 2023) *
Vrignaud et al.; "Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors," 2013; American Assn. for Cancer Research; Cancer Therapy: Preclinical, Vol. 19, No. 11, pp. 2973-2983. (Year: 2013) *
Vrignaud et al.; Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors," 2013; American Assn. for Cancer Research; Cancer Therapy: Preclinical, Vol. 19, No. 11, pp. 2973-2983. (Year: 2013) *
Yordanov; "Poly (alkyl cyanoacrylate) nanoparticles as drug carriers: 33 years later," 2012, SDCB Foundation; Bulgarian Journal of Chemistry, Vol. 1, Issue 2, pp. 61-72. (Year: 2012) *
Zhang et al.; ("Preparation, Characterization and biocompatibility of poly(ethylene glycol)-poly(n-butyl cyanoacrylate) nanocapsules with oil core via miniemulsion polymerization,"2008, ELSEVIER; European Polymer Journal, Vol. 44, pp. 1654-1661) (Year: 2008) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806330B2 (en) 2018-03-27 2023-11-07 Sintef Tto As PACA and cabazitaxel for anti-cancer treatment

Also Published As

Publication number Publication date
EP3946253A1 (en) 2022-02-09
EP3773471A1 (en) 2021-02-17
US20200061019A1 (en) 2020-02-27
BR112021019003A2 (pt) 2021-11-30
US11806330B2 (en) 2023-11-07
US20190298682A1 (en) 2019-10-03
WO2019185685A1 (en) 2019-10-03
JP2021519323A (ja) 2021-08-10
WO2020192950A1 (en) 2020-10-01
JP2022527858A (ja) 2022-06-06
CA3134923A1 (en) 2020-10-01
CN113840594A (zh) 2021-12-24
AU2019437385A1 (en) 2021-11-04
JP7550167B2 (ja) 2024-09-12
JP7317038B2 (ja) 2023-07-28
BR112020019452A2 (pt) 2021-01-05
CN111989087A (zh) 2020-11-24

Similar Documents

Publication Publication Date Title
Zhang et al. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities
Fusser et al. Cabazitaxel-loaded Poly (2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
Ismail et al. Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma
Yang et al. Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer
Chen et al. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance
Sriraman et al. Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid
Dai et al. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer
Song et al. Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles
Zhang et al. Enhancing solid tumor therapy with sequential delivery of dexamethasone and docetaxel engineered in a single carrier to overcome stromal resistance to drug delivery
Dai et al. Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes
Jiménez-López et al. Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes
Choudhury et al. Advanced nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with anticancer drug ‘Etoposide’
Zhu et al. The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles
US20210113482A1 (en) Poly (Alkyl Cyanoacrylate) Nanoparticles for Use in Treatment of Cancer
Zhao et al. A hindsight reflection on the clinical studies of poly (l‐glutamic acid)‐paclitaxel
Zhang et al. Multifunctional polyethylene glycol (PEG)-poly (lactic-co-glycolic acid)(PLGA)-based nanoparticles loading doxorubicin and tetrahydrocurcumin for combined chemoradiotherapy of glioma
Shang et al. Enhancing cancer chemo-immunotherapy by biomimetic nanogel with tumor targeting capacity and rapid drug-releasing in tumor microenvironment
Zhu et al. Delivery of acetylthevetin B, an antitumor cardiac glycoside, using polymeric micelles for enhanced therapeutic efficacy against lung cancer cells
Hyldbakk et al. Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models
Xue et al. A biodistribution study of solid lipid-polyethyleneimine hybrid nanocarrier for cancer RNAi therapy
Wang et al. Increased brain uptake of pterostilbene loaded folate modified micellar delivery system
Krajcer et al. Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy
Enteshari et al. Antitumor activity of raloxifene-targeted poly (styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice
Fathi-karkan et al. NPs loaded with zoledronic acid as an advanced tool for cancer therapy
Dave et al. Hybrid lipid-polymer nanoplatform: a systematic review for targeted colorectal cancer therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: OSLO UNIVERSITETSSYKEHUS HF, NORWAY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORCH, YRR;SCHMID, RUTH;SULHEIM, EINAR;AND OTHERS;REEL/FRAME:055144/0352

Effective date: 20200929

Owner name: SINTEF TTO AS, NORWAY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORCH, YRR;SCHMID, RUTH;SULHEIM, EINAR;AND OTHERS;REEL/FRAME:055144/0352

Effective date: 20200929

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: OSLO UNIVERSITETSSYKEHUS HF, NORWAY

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE 6TH INVENTOR'S NAME PREVIOUSLY RECORDED AT REEL: 055144 FRAME: 0352. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:MOERCH, YRR;SCHMID, RUTH;SULHEIM, EINAR;AND OTHERS;REEL/FRAME:058376/0064

Effective date: 20200929

Owner name: SINTEF TTO AS, NORWAY

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE 6TH INVENTOR'S NAME PREVIOUSLY RECORDED AT REEL: 055144 FRAME: 0352. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:MOERCH, YRR;SCHMID, RUTH;SULHEIM, EINAR;AND OTHERS;REEL/FRAME:058376/0064

Effective date: 20200929

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION